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Problem: To	determine	whether	amniotic	fluid	(AF)	CXCL10	concentration	is	associ-
ated	with	histologic	chronic	chorioamnionitis	in	patients	with	preterm	labor	(PTL)	and	
preterm	prelabor	rupture	of	the	membranes	(PROM).
Method of Study: This	study	included	168	women	who	had	an	episode	of	PTL	or	pre-
term	PROM.	AF	 interleukin	 (IL)-6	and	CXCL10	concentrations	were	determined	by	
immunoassay.
Results: (i)	Increased	AF	CXCL10	concentration	was	associated	with	chronic	(OR:	4.8;	
95%	CI:	1.7-	14),	but	not	acute	chorioamnionitis;	(ii)	increased	AF	IL-	6	concentration	
was	associated	with	acute	(OR:	4.2;	95%	CI:	1.3-	13.7)	but	not	chronic	chorioamnioni-
tis;	and	 (iii)	an	 increase	 in	AF	CXCL10	concentration	was	associated	with	placental	
lesions	consistent	with	maternal	anti-	fetal	rejection	(OR:	3.7;	95%	CI:	1.3-	10.4).	(iv)	All	
patients	with	elevated	AF	CXCL10	and	IL-	6	delivered	preterm.
Conclusion: Increased	AF	CXCL10	concentration	is	associated	with	chronic	chorioam-
nionitis	or	maternal	anti-	fetal	 rejection,	whereas	 increased	AF	 IL-	6	concentration	 is	
associated with acute histologic chorioamnionitis.
K E Y W O R D S
allograft, amniocentesis, biomarker, chorioamnionitis, chronic inflammation, cytokine, maternal 
anti-fetal	rejection
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1  | INTRODUCTION
Preterm labor is a syndrome characterized by the combination of 
increased uterine contractility, cervical remodeling (ie, ripening and 
dilatation), and decidual membrane activation, caused by multiple 
pathologic processes.1-12 One of the mechanisms of disease impli-
cated in preterm parturition is a breakdown of immune tolerance, 
which	may	evolve	into	maternal	anti-	fetal	rejection.13–30
The fetus and placenta express both maternal and paternal 
 antigens; therefore, they are semiallografts.31–42 The placenta is con-
sidered to be the most successful transplant in nature, a biological 
adaptation accomplished by immune tolerance.43–48 Tolerance is a 
specific	immunological	term	that	refers	to	“the	active	state	of	antigen-	
specific	 non-	responsiveness”49 leading to diminished reactivity to 
paternal antigens expressed by the placenta and/or fetus; it is con-
sidered key for successful pregnancy.31,33,39,40,50–53 The mechanisms 
responsible	for	tolerance	in	pregnancy	include	the	following:	(i)	T-	cell	
chemokine gene silencing in the decidual cells;54 (ii) a suppressive role 
of regulatory T cells;52,55–64	(iii)	expression	of	non-	classical	major	histo-
compatibility complex molecules on trophoblast cells that do not elicit 
a maternal immune response;65–70 (iv) changes in tryptophan catab-
olisms;71–75	 (v)	 T-	cell	 apoptosis;76,77 (vi) complement;78–90 and (vii) 
costimulatory molecules such as the programmed death ligand.91–93 
Other mechanisms for tolerance are not currently understood. The 
interested	reader	is	referred	to	recent	contributions	by	Sing	Sing	Way’s	
laboratory28,39,94–96	and	Adrian	Erlebacher.31,42,53
In transplantation medicine, failure of tolerance is responsible 
for	 graft	 rejection	 characterized	 by	 an	 infiltration	 of	 the	 recipient’s	
CD8+	(cytotoxic)	T	cells	into	the	graft	and	an	overexpression	of	C-	X-	C	
motif	 chemokine	 10	 (CXCL10),	 a	marker	 of	 allograft	 rejection.97–102 
In obstetrics, rejection as a mechanism of disease has been largely 
overlooked.	 However,	 recent	 evidence	 suggests	 that	maternal	 anti-	
fetal rejection is operative in a subset of patients with spontaneous 
preterm labor,15,16,20,26,103 preterm prelabor rupture of the membranes 
(PROM),20 fetal death,17,25 recurrent abortion,19 and other obstetrical 
syndromes.14,18,21–24,103	 Maternal	 lymphocytes	 (akin	 to	 a	 transplant	
recipient) can infiltrate the chorioamniotic membranes (fetal tissue or 
semiallograft), lead to chronic chorioamnionitis,15,26 and induce tro-
phoblast apoptosis, which, when excessive, can result in graft failure 
(eg, membrane rupture or activation of the decidual membrane and 
the initiation of labor).15,104 The chemotactic signal inducing the migra-
tion of maternal T lymphocytes into the chorioamniotic membranes 
appears to be present in the amniotic cavity. One such chemokine is 
CXCL10,15,104,105 and an increased concentration of this chemokine in 
the amniotic fluid has been characterized by our group to represent a 
distinct	form	of	intra-	amniotic	inflammation,	which	is	associated	with	
chronic inflammatory lesions of the placenta and a novel form of fetal 
inflammatory	response	syndrome	(FIRS)	or	FIRS	type	2.21
This	 distinct	 form	 of	 intra-	amniotic	 inflammation	 differs	 from	
the	 intra-	amniotic	 inflammatory	 process	 observed	 in	 patients	 with	
preterm	labor	due	to	microbial	invasion	of	the	amniotic	cavity	(MIAC).	
Microorganisms	and	their	products	can	induce	a	robust	intra-	amniotic	
inflammatory response characterized by an elevation in amniotic fluid 
interleukin	(IL)-6	concentration,106–130 and neutrophil chemokines, such 
as	IL-	8,111–113,131–140 as well as other inflammatory mediators capable 
of inducing the onset of labor.118,135,141–180 Recently, we provided an 
analysis of the protein inflammatory network for this condition.181 
The	histologic	hallmark	of	MIAC	 is	acute	histologic	chorioamnionitis,	
defined by the infiltration of maternal neutrophils into the chorioam-
niotic membranes.109,182–196 Related lesions are chorionic vasculitis197 
and the spectrum of lesions observed in cases of funisitis.155,196,198–204 
Therefore,	at	this	time,	at	least	two	major	types	of	intra-	amniotic	inflam-
mation appear to occur in the context of spontaneous preterm labor—
one	associated	with	MIAC	or	induced	by	danger	signals124,205–209 and 
the other associated with chronic inflammatory lesions of the placenta 
(often	attributed	to	maternal	anti-	fetal	rejection).
The	concentration	of	the	T-	cell	chemokine	CXCL10	(IP-	10)	is	con-
sidered a marker for chronic inflammatory lesions associated with 
allograft rejection and chronic chorioamnionitis in the case of preg-
nancy.	In	contrast,	IL-	6,	IL-	8,	IL-	1,	and	TNF-	α are examples of cytokines 
involved in acute inflammatory lesions of the placenta.109,128,130,196,210
The objective of this study was to determine the prevalence and 
clinical	significance	of	an	elevated	CXCL10	concentration	in	the	amni-
otic fluid of patients with a diagnosis of either preterm labor with intact 
membranes	or	preterm	PROM	and	whether	an	elevation	in	CXCL10	con-
centration is associated with chronic chorioamnionitis, as an increased 
concentration	of	 IL-	6	 and	CXCL10	 is	 frequently	observed	 in	patients	
with	intra-	amniotic	infection	and	acute	histologic	chorioamnionitis.
2  | MATERIALS AND METHODS
2.1 | Study population
A	nested	retrospective	cohort	study	was	conducted	by	searching	the	
clinical	 database	 and	 Bank	 of	 Biological	 Materials	 of	Wayne	 State	
University,	the	Detroit	Medical	Center,	and	the	Perinatology	Research	
Branch of the Eunice Kennedy Shriver National Institute of Child Health 
and	Human	Development	 (NICHD)	 (Detroit,	MI)	 to	 identify	patients	
with a diagnosis of spontaneous preterm labor with intact membranes 
or	 preterm	 PROM.	 Patients	 were	 included	 if	 they	 met	 the	 follow-
ing criteria: (i) singleton gestation; (ii) episode of preterm labor and 
intact or ruptured membranes; and (iii) transabdominal amniocentesis 
performed between 20 and 35 weeks of gestation for microbiologi-
cal studies. Patients were excluded if chromosomal or structural fetal 
anomalies	or	placenta	previa	was	present.	All	patients	provided	writ-
ten informed consent. The use of biological specimens and clinical 
data for research purposes was approved by the Institutional Review 
Boards	of	NICHD	and	Wayne	State	University.
2.2 | Biological samples and analysis
Amniotic	fluid	was	transported	in	a	capped	sterile	syringe	to	the	clini-
cal laboratory where it was cultured for aerobic and anaerobic bac-
teria, including genital mycoplasmas. Evaluations of the white blood 
cell count, glucose concentration, and Gram stain of the amniotic fluid 
were	performed	shortly	after	collection.	Amniotic	fluid	was	centrifuged	
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at 1300 g for 10 minutes at 4°C shortly after collection and stored at 
−70°C	until	analysis.	Concentrations	of	IL-6	and	CXCL10	in	the	amni-
otic	 fluid	 (ng/mL)	 were	 determined	 by	 the	 enzyme-linked	 immuno-
sorbent assay test, using immunoassays obtained from R&D Systems 
(Minneapolis,	MN,	USA).	The	assay	time,	volume,	and	other	characteris-
tics for each method have been previously described.15,123,124,169,205–207
2.3 | Clinical definitions
Gestational age was determined by the last menstrual period and con-
firmed by ultrasound examination, or by ultrasound examination alone 
if the sonographic determination of gestational age was not consistent 
with menstrual dating.211 Preterm labor was diagnosed by the pres-
ence of at least two regular uterine contractions every 10 minutes in 
association with cervical changes in patients with a gestational age 
between 20 and 36 6/7 weeks that led to preterm delivery (defined 
as	birth	prior	to	the	37th	week	of	gestation).	Preterm	PROM	was	diag-
nosed by a sterile speculum examination with documentation of the 
pooling of amniotic fluid in the vagina in association with a positive 
nitrazine test and/or positive ferning test when necessary. Elevated 
amniotic	 fluid	 IL-	6	 concentration	 (≥2.6	ng/mL)	 was	 used	 to	 define	
intra-	amniotic	 inflammation.176,205–208,212–215	MIAC	was	defined	as	a	
positive	amniotic	fluid	culture.	Intra-	amniotic	infection	was	defined	as	
the	combination	of	MIAC	and	intra-	amniotic	inflammation.	An	elevated	
amniotic	fluid	CXCL10	concentration	as	a	marker	of	subclinical	intra-	
amniotic	inflammation	was	defined	as	≥2.2	ng/mL,	which	is	above	the	
95th percentile among patients with uncomplicated term deliveries.169
The diagnosis of acute histologic chorioamnionitis was based on 
the presence of acute inflammatory changes in the extraplacental cho-
rioamniotic membrane roll and/or chorionic plate of the placenta, using 
the criteria previously described.188–190,192,196,216,217 The grading and 
staging of placental lesions consistent with amniotic fluid infection was 
defined	according	to	the	Amniotic	Fluid	Infection	Nosology	Committee	
of the Perinatal Section of the Society for Pediatric Pathology as 
reported by Redline et al.188	Acute	funisitis	was	defined	as	the	presence	
of	 neutrophils	 in	 the	wall	 of	 the	 umbilical	 vessels	 and/or	Wharton’s	
jelly.188,196,197 Chronic placental inflammatory lesions included the 
following: (i) chronic chorioamnionitis; (ii) villitis of unknown etiology 
(VUE); and (iii) chronic deciduitis. Chronic chorioamnionitis was diag-
nosed when lymphocytic infiltration into the chorionic trophoblast 
layer or chorioamniotic connective tissue was observed.14,15,26,218 VUE 
was defined as the presence of lymphohistiocytic infiltration, in varying 
proportion, of the placental villous tree.14,219 Chronic deciduitis was 
diagnosed as the presence of lymphocytic infiltration into the decidua 
of the basal plate.220	Lesions	consistent	with	maternal	anti-	fetal	rejec-
tion proposed by our group included chronic chorioamnionitis, VUE, or 
chronic deciduitis with plasma cells.14,16
2.4 | Study groups
Participants were allocated into four study groups, according to 
whether	 they	had	 an	 increase	 in	 amniotic	 fluid	CXCL10	 concentra-
tion	and/or	an	increase	in	amniotic	fluid	IL-6	concentration:	(i)	normal	
amniotic	fluid	IL-	6	and	CXCL10	concentrations;	(ii)	an	isolated	increase	
in	amniotic	fluid	IL-	6	concentration;	(iii)	an	isolated	increase	in	amni-
otic	fluid	CXCL10	concentration;	and	(iv)	an	increase	in	both	amniotic	
fluid	 IL-	6	and	CXCL10	concentrations.	The	cutoff	has	been	derived	
from previous studies.109,111,169
2.5 | Study outcomes
The primary outcome of this study was the presence or absence of 
acute or chronic chorioamnionitis, defined as (i) the absence of both 
acute	and	chronic	chorioamnionitis;	(ii)	acute	chorioamnionitis	≥stage	
2 in the absence of chronic chorioamnionitis; (iii) chronic chorioam-
nionitis	in	the	absence	of	acute	histologic	chorioamnionitis	≥stage	2;	
and	(iv)	the	presence	of	both	acute	(≥stage	2)	and	chronic	chorioam-
nionitis. The presence of placental lesions associated with maternal 
anti-	fetal	rejection	was	examined	as	a	secondary	outcome.217
2.6 | Statistical analysis
The	Kolmogorov-	Smirnov	test	was	used	to	assess	the	normality	of	arith-
metic	data	distributions.	The	Kruskal-	Wallis	test	and	the	Mann-	Whitney	
U test were used to make comparisons among and between groups for 
arithmetic	variables.	The	chi-square	test	or	Fisher’s	exact	test	was	used	
for	comparisons	of	proportions.	Multinomial	logistic	regression	models	
were fit to examine magnitudes of association with primary and second-
ary outcomes, adjusting for gestational age at amniocentesis. Statistical 
analysis	 was	 performed	 using	 SAS	 9.4	 (Cary,	 NC,	 USA).	 Confidence	
intervals (95% CI) that do not include the null hypothesis (ie, an odds 
ratio	[OR]	of	“1.0”)	are	considered	statistically	significant.
3  | RESULTS
3.1 | Clinical characteristics
One	hundred	and	sixty-	eight	women	with	either	preterm	labor	with	
intact	membranes	(72%)	or	preterm	PROM	(28%)	were	included	in	this	
study. Table 1 displays the clinical characteristics of the participants; 
88%	were	African	American,	34%	were	nulliparous,	 and	83%	deliv-
ered preterm (<37 weeks of gestation). The median gestational age at 
amniocentesis	was	30	weeks	(interquartile	range:	27-	32	weeks),	and	
amniotic fluid cultures were positive in 20% of the study participants. 
Placental lesions associated with acute and chronic histologic cho-
rioamnionitis	and	maternal	anti-	fetal	rejection	were	observed	in	49%	
(82/168), 27% (45/168), and 41% (69/168) of the study population, 
respectively.
3.2 | Amniotic fluid CXCL10 and IL- 6 concentrations 
according to placental pathologic lesions and 
outcome of pregnancy
Amniotic	fluid	CXCL10	concentrations	were	highest	in	patients	with	
chronic	chorioamnionitis	(Figure	1),	whereas	amniotic	fluid	IL-	6	con-
centrations were highest in patients with acute chorioamnionitis 
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≥stage	2	(Figure	2).	Clinical	characteristics	and	the	prevalence	of	acute	
and chronic inflammatory placental lesions for the four study groups, 
defined	 according	 to	 the	 amniotic	 fluid	 CXCL10	 and	 amniotic	 fluid	
IL-	6	concentrations,	are	shown	in	Table	2.
An	elevation	in	the	concentration	of	both	amniotic	fluid	CXCL10	
(≥2.2	ng/mL)	 and	 amniotic	 fluid	 IL-	6	 (≥2.6	ng/mL)	 was	 observed	 in	
35% (59/168) of the patients, whereas 18% (30/168) had an iso-
lated	elevation	 in	 the	 concentration	of	 amniotic	 fluid	CXCL10,	15%	
(26/168) had an isolated elevation in the concentration of amniotic 
fluid	 IL-	6,	 and	 32%	 (53/168)	 did	 not	 have	 an	 elevation	 in	 amniotic	
fluid	 concentrations	of	either	CXCL10	or	 IL-	6.	All	patients	with	ele-
vated	concentrations	of	both	amniotic	fluid	CXCL10	and	IL-	6	delivered	
before 37 weeks of gestation. By contrast, 93% (24/26) of patients 
with	an	isolated	elevation	in	the	concentration	of	amniotic	fluid	IL-	6	
and 77% (23/30) of those with an isolated elevation in the concentra-
tion	of	amniotic	fluid	CXCL10	delivered	preterm.
3.3 | Acute and chronic chorioamnionitis in 
relationship to amniotic fluid concentrations of 
CXCL10 and IL- 6
The prevalence of chronic chorioamnionitis was highest in patients 
with	 an	 isolated	 elevation	 in	 amniotic	 fluid	 CXCL10	 concentration	
(46.7%; 14/30) and was lowest in those with an isolated elevation 
in	 amniotic	 fluid	 IL-	6	 concentration	 (7.7%;	 2/26)	 (Table	2).	 In	 con-
trast,	the	prevalence	of	acute	chorioamnionitis	≥stage	2	was	highest	
in	patients	with	an	isolated	elevation	in	both	amniotic	fluid	IL-	6	and	
CXCL10	concentrations	(52.5%;	31/59),	followed	by	patients	with	an	
isolated	elevation	in	amniotic	fluid	IL-	6	concentration	(42.3%;	11/26).	
The prevalence of such placental lesions was observed in 13% (4/30) 
of	patients	with	an	isolated	elevation	in	amniotic	fluid	CXCL10	con-
centration. Interestingly, almost all patients with acute and chronic 
chorioamnionitis (83.3%; 5/6) had an elevation in both amniotic fluid 
IL-	6	and	CXCL10	concentrations	(Table	2).
The magnitudes of association between the study groups accord-
ing	 to	amniotic	 fluid	CXCL10	and	 IL-	6	concentrations	and	 the	pres-
ence or absence of acute or chronic chorioamnionitis are described in 
Figure	3.	Patients	with	an	isolated	elevation	in	CXCL10	concentration	
were significantly more likely to have chronic, but not acute, chorio-
amnionitis	 (OR:	 4.8,	 95%	CI:	 1.7-	14;	 and	OR:	 2.1,	 95%	CI:	 0.5-	8.9,	
respectively)	than	those	with	normal	amniotic	fluid	CXCL10	and	IL-	6	
concentrations, after adjusting for gestational age at amniocentesis. 
In	contrast,	patients	with	an	 isolated	elevation	 in	amniotic	 fluid	 IL-	6	
concentration	were	significantly	more	likely	to	have	acute	(≥stage	2),	
but	not	chronic,	chorioamnionitis	(OR:	4.2,	95%	CI:	1.3-	13.7;	and	OR:	
0.5,	 95%	CI:	 0.1-	2.8,	 respectively)	 than	 those	with	 normal	 amniotic	
fluid	CXCL10	and	IL-	6	concentrations.	An	elevation	in	amniotic	fluid	
concentrations	of	both	CXCL10	and	 IL-	6	was	associated	with	acute	
F IGURE  1 The	median	concentration	of	AF	CXCL10	in	patients	
according to the presence or absence of acute chorioamnionitis 
(≥stage	2)	or	chronic	chorioamnionitis.	The	median	(interquartile	
range:	IQR)	concentration	of	AF	CXCL10	(ng/mL)	was	highest	
in patients with chronic chorioamnionitis. The median (IQR) 
concentration	of	AF	CXCL10	(ng/mL)	was	1.6	(0.9-	3.4),	3.1	
(1.1-	6.9),	4.1	(1.9-	7.7),	and	3.9	(3.0-	9.7)	in	patients	with	neither	
acute chorioamnionitis nor chronic chorioamnionitis, acute 
chorioamnionitis	(≥stage	2),	chronic	chorioamnionitis,	and	acute	and	
chronic	chorioamnionitis,	respectively.	AF,	amniotic	fluid;	CXCL,	C-	
X-	C	motif	chemokine;	acute	chorioamnionitis,	the	presence	of	acute	
chorioamnionitis	≥stage	2	in	the	absence	of	chronic	chorioamnionitis;	
chronic chorioamnionitis, the presence of chronic chorioamnionitis in 
the	absence	of	acute	chorioamnionitis	≥stage	2
TABLE  1 Descriptive characteristics of the study population
Descriptive characteristics
Median (IQR)  
or % (n)
Maternal	age	(y) 24.0	(20.3-	30.0)
Body mass index (kg/m2) 25.0	(21.0-	30.9)
Nulliparity (%) 33.9% (57/168)
Gestational age at amniocentesis (wk) 30.2	(26.6-	32.3)
African	American	ethnicity	(%) 88.1% (148/168)
Amniotic	fluid	WBC	count	(cells/mm3) 3.5	(0-	39.3)
Amniotic	fluid	glucose	(mg/dL) 23.0	(10.0-	30.0)
Positive amniotic fluid culture (%) 20.2% (34/168)
Amniocentesis-	to-	delivery	interval	(d) 4	(1-	26.8)
Preterm delivery (%) 83.3% (140/168)
Gestational age at delivery (wk) 32.1	(27.7-	34.9)
Birthweight (g) 1822.5 
(1086.3-	2472.5)
Acute	histologic	chorioamnionitis	(%) 48.8% (82/168)
Chronic chorioamnionitis (%) 26.8% (45/168)
Placental lesions associated with maternal 
anti-	fetal	rejection	(%)*
41.1% (69/168)
Data presented as median (IQR) or % (n).
IQR,	interquartile	range;	WBC,	white	blood	cell.
*Placental	 lesions	 associated	 with	 maternal	 anti-	fetal	 rejection:	 chronic	
chorioamnionitis, villitis of unknown etiology (VUE), and chronic deciduitis 
with plasma cells.
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(≥stage	2)	and	chronic	chorioamnionitis	(OR:	9.6,	95%	CI:	3.1-	30;	and	
OR:	3.8,	95%	CI:	1.3-	11.6,	respectively).	None	of	the	patients	whose	
placentas	 had	 both	 acute	 (≥stage	 2)	 and	 chronic	 chorioamnionitis	
(n=6)	had	normal	amniotic	fluid	CXCL10	and	IL-	6	concentrations.
The magnitudes of association observed between the study groups 
are	shown	in	Figure	4	in	accord	with	the	concentrations	of	both	amniotic	
fluid	CXCL10	and	IL-6	as	well	as	the	placental	lesions	associated	with	
maternal	anti-fetal	rejection.	Patients	with	an	elevation	in	amniotic	fluid	
CXCL10		concentration	were	significantly	more	likely	to	have	placental	
lesions	associated	with	maternal	anti-	fetal	rejection,	but	not	acute	cho-
rioamnionitis	(≥stage	2),	than	those	with	normal	amniotic	fluid	CXCL10	
and	IL-	6	concentrations,	adjusting	for	gestational	age	at	amniocentesis	
(OR:	3.7,	95%	CI:	1.3-	10.4;	and	OR:	1.6,	95%	CI:	0.3-	8.3,	respectively).
The	 combination	 of	 both	 acute	 chorioamnionitis	 (≥stage	 2)	 and	
placental	lesions	associated	with	maternal	anti-	fetal	rejection	was	not	
observed	 in	patients	without	an	elevation	 in	amniotic	 fluid	 IL-	6	and	
CXCL10	concentrations	(Figure	4).
4  | DISCUSSION
4.1 | Principal findings of the study
(i)	 An	 isolated	 elevation	 in	 amniotic	 fluid	 CXCL10	 concentra-
tion	 is	 associated	with	 chronic,	 but	 not	 acute	 (≥stage	 2),	 histologic	
chorioamnionitis; (ii) in contrast, an isolated elevation in amniotic 
fluid	IL-	6	concentration	was	associated	with	acute	(≥stage	2),	but	not	
chronic, histologic chorioamnionitis; (iii) similar findings were observed 
in	 relation	 to	 placental	 lesions	 associated	 with	 maternal	 anti-	fetal	
rejection (chronic chorioamnionitis, VUE, and/or chronic deciduitis 
with plasma cells). Specifically, an isolated elevation in amniotic fluid 
CXCL10	concentration	is	associated	with	the	subsequent	delivery	of	
placentas	with	lesions	consistent	with	maternal	anti-	fetal	rejection	but	
not	acute	histologic	chorioamnionitis	(≥stage	2);	(iv)	elevation	in	both	
CXCL10	and	IL-	6	is	associated	with	acute	and	chronic	inflammatory	
lesions of the placenta, as well as the combination of lesions suggest-
ing that a complex pathologic state representing a mixture of maternal 
anti-	fetal	rejection	and	infection	may	lead	to	early	preterm	delivery	in	
these	cases;	 and	 (v)	 all	patients	with	elevated	AF	concentrations	of	
both	CXCL10	and	IL-	6	delivered	prematurely.
4.2 | Two types of intra- amniotic inflammation in 
preterm labor
4.2.1 | Microbial- associated and sterile intra- 
amniotic inflammation
Preterm parturition is a syndrome caused by multiple etiolo-
gies.2,4,6-8,12	Intra-	amniotic	infection	is	present	in	one	of	every	three	
preterm	deliveries	and	 is	even	more	 frequent	 in	cases	of	spontane-
ous preterm labor with intact membranes.221–226	Microorganisms	are	
detected	 in	 the	amniotic	cavity	 in	25-	40%	of	patients	with	preterm	
labor and intact membranes who deliver preterm133,221–234 and in 
50-	75%	of	those	with	preterm	PROM	at	the	time	of	 labor	onset.235 
The earlier the gestational age at presentation, the greater the risk of 
MIAC	or	intra-	amniotic	infection.6,12,225,226,233,236–238
The current study found that 79.8% (134/168) of patients with 
preterm	 labor/PROM	 have	 no	 evidence	 of	 MIAC,	 suggesting	 the	
important role of sterile inflammation of the amniotic cavity. Using a 
combination	of	cultivation	and	molecular	techniques,	we	have	previ-
ously	reported	that	only	a	fraction	of	all	patients	with	intra-	amniotic	
inflammation	(defined	as	an	increase	in	amniotic	fluid	IL-	6	concentra-
tion) have microorganisms present in the amniotic cavity; therefore, 
sterile	intra-	amniotic	fluid	inflammation	has	emerged	as	an	important	
mechanism of disease in preterm labor.124,205–207,209 Danger signals 
released during the course of cellular stress, necrosis, pyroptosis, 
and	senescence	as	well	as	other	non-	microbial	 injury	can	trigger	an	
inflammatory response in the absence of microorganisms.214,239–256 
Danger signals may also participate in the sterile inflammatory 
response associated with spontaneous labor at term and are prob-
ably mediated by activation of the inflammasomes.244,257–261 Recent 
evidence	suggests	that	the	intra-	amniotic	administration	of	alarmins	
such	as	HMGB1	can	induce	preterm	parturition	in	mice262 and that 
this cytokine can induce a robust immune response characterized 
by	secretion	of	IL-	6	and	IL-	1β from human fetal membranes,263 sug-
gesting a role for the inflammasomes in the mechanisms leading to 
premature labor in cases of sterile inflammation.124,214,250 Thus, this 
mechanism	may	 be	 involved	 in	 patients	with	 sterile	 intra-	amniotic	
F IGURE  2 The	median	concentration	of	AF	IL-6	in	patients	with	
acute	chorioamnionitis	≥stage	2	and/or	chronic	chorioamnionitis.	The	
median	(interquartile	range:	IQR)	AF	concentration	of	IL-	6	(ng/mL)	
was	highest	in	patients	with	acute	chorioamnionitis	≥stage	2.	The	
median	(IQR)	AF	concentration	of	IL-	6	(ng/mL)	was	1.5	(0.6-	4.2),	41.6	
(5.3-	20.7),	1.6	(0.7-	5.4),	and	17.6	(3.9-	167.4)	in	patients	with	neither	
acute nor chronic chorioamnionitis, acute chorioamnionitis, chronic 
chorioamnionitis, or acute and chronic chorioamnionitis, respectively. 
AF,	amniotic	fluid;	IL,	interleukin;	acute	chorioamnionitis,	the	
presence	of	acute	chorioamnionitis	≥stage	2	in	the	absence	of	
chronic chorioamnionitis; chronic chorioamnionitis, the presence of 
chronic chorioamnionitis in the absence of acute chorioamnionitis 
≥stage	2;	*P value <.05
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inflammation	characterized	by	elevated	amniotic	fluid	IL-	6	concentra-
tions	and	acute	histologic	chorioamnionitis.	Moreover,	a	fraction	of	
patients included in this study had elevated concentrations of amni-
otic	fluid	IL-6	and	CXCL10;	these	patients	delivered	preterm	and	had	
an odds ratio of 10.9 for acute histologic chorioamnionitis and 4.3 
for	placental	lesions	consistent	with	maternal	anti-	fetal	rejection.	The	
role of the interaction between the acute inflammatory processes 
that activate the inflammasome and involve fetal rejection is yet to 
be discovered.
When	 bacteria	 and	 other	 microorganisms	 are	 present	 in	 the	
amniotic cavity and elicit an inflammatory response, a wide range of 
chemokines	and	cytokines,	such	as	IL-	8,111–113,131–140	IL-	6,106–113,115–
121,123–126,128–130	 monocyte	 chemotactic	 protein-	1,164,165	 CXCL10	
(IP-	10),128,169	 macrophage	 inflammatory	 protein-	1α,264,265	 growth-	
regulated	 oncogene	 (GRO)-	α,135	 and	 other	 inflammation-related	
proteins118,141–163,166–168,170–176,179,266 are produced, and this can 
result in the chemotaxis of inflammatory cells to the chorioamniotic 
membranes.	 Among	 these	 inflammation-related	 proteins,	 IL-	6	 has	
become	the	key	cytokine	for	the	diagnosis	of	intra-	amniotic	inflam-
mation because its increase in concentration has been associated 
with a shorter interval to delivery and an increased rate of neonatal 
morbidity and mortality.109,124,267,268	Recently,	an	 in-	depth	analysis	
of the chemokine network in preterm labor with and without inflam-
mation,	sterile	 inflammation,	and	 intra-	amniotic	 infection	has	been	
reported.269 Network analysis provides a greater level of insight into 
the biology of the process, given that the protein inflammatory pro-
cess operates through a network rather than single molecules.269 
Collectively,	 amniotic	 fluid	 IL-	6	 is	 a	 pragmatic	 marker	 of	 either	
microbial-	associated	or	sterile	intra-	amniotic	inflammation.	With	the	
development	of	high-fidelity	assays	that	allow	multiplex	analysis	of	
biological fluids, we anticipate that it will be possible to characterize 
with greater detail the biology of the immune response, timetable, 
response to therapy, and other important clinical characteristics.
4.2.2 | A novel form of intra- amniotic inflammation 
characterized by CXCL10
We	previously	identified	a	form	of	intra-	amniotic	inflammation	char-
acterized	 by	 an	 increase	 in	 CXCL10	 concentration15,169 associated 
with chronic chorioamnionitis, the most common  placental lesion 
in late spontaneous preterm delivery.22	 This	 form	 of	 	intra-	amniotic	
inflammation	 is	 considered	 a	 manifestation	 of	 maternal	 anti-	fetal	
rejection,15,22,26,169 as an infectious cause has not been identified by 
the use of cultivation and molecular methods.
Compelling	 evidence	 suggests	 that	 CXCL10	 plays	 an	 import-
ant role in the pathogenesis of graft failure and rejection in other 
organ systems.97–102	 Overexpression	 of	 this	 T-	cell	 chemokine	 has	
been observed in the serum/plasma,270,271 urine,272,273 and tis-
sue biopsies99,274–276 from patients who experienced rejection in 
cases of kidney,270,277–282 heart,283–285 lung,271,274 and vascular 
F IGURE  3 Magnitudes	of	association	between	the	study	groups	according	to	amniotic	fluid	IL-	6	and	CXCL10	concentrations	and	the	
presence	or	absence	of	acute	(≥stage	2)	or	chronic	chorioamnionitis.	Results	were	obtained	by	fitting	a	multinomial	logistic	regression	model	
and	adjusting	for	gestational	age	at	amniocentesis.	AF,	amniotic	fluid;	CXCL,	C-	X-	C	motif	chemokine;	IL,	interleukin.	Normal	AF	IL-	6	and	CXCL10	
concentrations:	IL-	6	<2.6	ng/mL	and	CXCL10	<2.2	ng/mL;	isolated	increase	in	AF	IL-	6	concentration:	IL-	6	≥2.6	ng/mL;	isolated	increase	in	AF	
CXCL10	concentration:	CXCL10	≥2.2	ng/mL;	increase	in	both	AF	IL-	6	and	CXCL10	concentrations:	IL-	6	≥2.6	ng/mL	and	CXCL10	≥2.2	ng/mL.	
Acute	chorioamnionitis:	the	presence	of	acute	chorioamnionitis	≥stage	2	in	the	absence	of	chronic	chorioamnionitis;	chronic	chorioamnionitis:	
the	presence	of	chronic	chorioamnionitis	in	the	absence	of	acute	chorioamnionitis	≥stage	2.	None	of	the	patients	grouped	by	their	normal	AF	IL-	
6	and	CXCL10	concentrations	had	both	acute	and	chronic	placental	inflammatory	lesions;	therefore,	the	computation	of	the	odds	ratios	relative	
to the common reference cannot be performed. Red values indicate statistically significant associations between the study group on the left and 
the outcome named in the column header
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transplantation.286–288	 Moreover,	 there	 is	 a	 significant	 correlation	
between	 serum/plasma	CXCL10	 concentrations	 and	 the	 timing	 and	
severity of allograft rejection.100,270,271,279,285
In chronic chorioamnionitis, which can be considered a form of 
allograft	 rejection,	 there	 is	 an	upregulation	of	CXCL9,	CXCL10,	 and	
CXCL11	 mRNA	 expression	 in	 the	 chorioamniotic	 membranes.15 
Upregulation	 of	 CXC	 chemokines	 for	 CXCR3+	 (receptor	 for	 T-	cell	
chemokines) cells in the chorioamniotic membranes is associated with 
a	 higher	median	 amniotic	 fluid	 T-	cell	 chemokine	 (CXCL10)	 concen-
tration, and also chronic chorioamnionitis, presumably by stimulating 
amniotrophic	maternal	T-	cell	migration	 to	 the	 chorioamniotic	mem-
branes.15 This placental lesion represents a manifestation of maternal 
anti-	fetal	 rejection	as	demonstrated	by:	 (i)	higher	maternal	anti-	fetal	
human	leukocyte	antigen	(HLA)	sensitization18 in patients with chronic 
chorioamnionitis than in those without this lesion; (ii) complement 
deposition	(C4d),	a	surrogate	marker	of	antibody-	mediated	rejection,	
in the umbilical vein;16,23,24 and (iii) the presence of a novel form of fetal 
systemic	inflammation	(FIRS	type	2)	in	the	setting	of	chronic	chorio-
amnionitis.	The	transcriptome	of	the	umbilical	cord	blood	in	FIRS	type	
2	is	different	from	that	of	FIRS	type	1,	indicating	that	this	is	a	differ-
ent condition.21	Moreover,	a	proteomic	analysis	of	the	amniotic	fluid	
from patients with chronic chorioamnionitis demonstrated that these 
patients	have	lower	amniotic	fluid	concentrations	of	glycodelin-	A,289 a 
protein implicated in the maintenance of maternal tolerance against a 
semiallogeneic fetus.290
Interestingly, approximately 40% of placentas with chronic cho-
rioamnionitis	 from	 patients	 with	 preterm	 labor	 or	 preterm	 PROM	
have concomitant VUE and chronic deciduitis with plasma cells.15	We	
demonstrated the systemic derangement of the chemokine concen-
trations that occurred in the maternal and fetal circulation systems of 
patients with VUE, which was distinct from that observed in the set-
ting of acute chorioamnionitis.14	The	mRNA	expression	of	a	subset	of	
chemokines	and	their	receptors	(CXCL9,	CXCL10,	CXCL11,	CXCL13,	
and	CXCR3)	was	also	higher	in	VUE	placentas	than	in	normal	placen-
tas.14	Moreover,	the	median	concentrations	of	CXCL9,	CXCL10,	and	
CXCL11	in	maternal	and	fetal	plasma	were	higher	in	patients	with	VUE	
than in those without this lesion.14 Therefore, we also consider VUE as 
a	manifestation	of	maternal	anti-	fetal	rejection	unless	a	microorganism	
can be identified.
In	 summary,	 intra-	amniotic	 inflammation	 associated	with	mater-
nal	anti-	fetal	rejection	differs	from	microbial-associated	intra-amniotic	
inflammation;	 it	 is	characterized	by	an	elevation	 in	T-	cell	chemokine	
concentration in the amniotic fluid and chorioamniotic membranes as 
well as the presence of chronic inflammatory lesions of the placenta.
F IGURE  4 Magnitudes	of	association	between	the	study	groups	on	the	left	and	the	outcomes	listed	in	the	column	heading	at	the	top.	
Results	were	obtained	by	fitting	a	multinomial	logistic	regression	model	and	adjusting	for	gestational	age	at	amniocentesis.	AF,	amniotic	fluid;	
CXCL,	C-	X-	C	motif	chemokine;	IL,	interleukin.	Normal	AF	IL-	6	and	CXCL10	concentrations:	IL-	6	<2.6	ng/mL	and	CXCL10	<2.2	ng/mL;	isolated	
increase	in	AF	IL-	6	concentration:	IL-	6	≥2.6	ng/mL;	isolated	increase	in	AF	CXCL10	concentration:	CXCL10	≥2.2	ng/mL;	increase	in	both	AF	
IL-	6	and	CXCL10	concentrations:	IL-	6	≥2.6	ng/mL	and	CXCL10	≥2.2	ng/mL.	Acute	chorioamnionitis:	the	presence	of	acute	chorioamnionitis	
≥stage	2	in	the	absence	of	chronic	chorioamnionitis;	chronic	chorioamnionitis:	the	presence	of	chronic	chorioamnionitis	in	the	absence	of	acute	
chorioamnionitis	≥stage	2;	placental	lesions	associated	with	maternal	anti-	fetal	rejection:	chronic	chorioamnionitis,	villitis	of	unknown	etiology	
(VUE),	and	chronic	deciduitis	with	plasma	cells.	None	of	the	patients	grouped	by	their	normal	AF	IL-	6	and	CXCL10	concentrations	had	both	
acute and chronic placental inflammatory lesions; therefore, the computation of the odds ratios relative to the common reference cannot be 
performed. Red values indicate statistically significant associations between the study group on the left and the outcome named in the column 
header
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4.3 | CXCL10: a biomarker for chronic placental 
inflammatory lesions
The	 results	 of	 the	 study	herein	 support	 the	 view	 that	CXCL10	 is	 a	
marker for chronic inflammatory lesions of the placenta. Our findings 
are consistent with those of Gervasi et al.,169	who	reported	that	mid-	
trimester	 amniotic	 fluid	 CXCL10	 concentrations	 >502	pg/mL	 were	
associated	with	late	(>32	weeks)	spontaneous	preterm	delivery	(OR:	
3.9;	95%	CI:	1.6-	9.9),	whereas	elevated	amniotic	fluid	IL-	6	concentra-
tions	(>1740	pg/mL)	were	associated	with	a	higher	risk	of	spontane-
ous preterm delivery prior to 32 weeks of gestation (OR: 9.5; 95% 
CI:	2.9-31.1).	Our	study	differs	in	that	we	examined	the	relationship	
between	 the	 isolated	 elevation	 in	 either	 amniotic	 fluid	 CXCL10	 or	
amniotic	fluid	IL-6	concentration	and	the	association	with	both	acute	
and chronic histologic chorioamnionitis.
4.4 | What is the significance of an elevation in the 
concentrations of amniotic fluid IL-6 and CXCL10?
Thirty-	five	percent	(59/168)	of	patients	in	this	study	had	elevated	
amniotic	fluid	concentrations	of	both	IL-	6	and	CXCL10.	All	of	them	
had spontaneous preterm delivery <37 weeks and <34 weeks of 
gestation, respectively, suggesting a severe inflammatory process 
associated	with	preterm	delivery.	Moreover,	patients	with	an	eleva-
tion	in	both	amniotic	fluid	IL-	6	and	CXCL10	concentrations	had	a	sig-
nificantly	higher	frequency	of	spontaneous	preterm	delivery	within	
48 hours of amniocentesis than those with an isolated elevation in 
amniotic	fluid	CXCL10	concentration	 (Table	2).	 Indeed,	a	systemic	
fetal inflammatory response (defined as the presence of funisitis or 
chorionic vasculitis)197 was detected in 54.2% (32/59) of patients 
with	an	elevation	in	both	amniotic	fluid	CXCL10	and	IL-	6	concentra-
tions, but in only 34.6% (9/26) and 20% (6/30) of patients with an 
isolated	elevation	 in	amniotic	 fluid	 IL-	6	or	CXCL10	concentration,	
respectively (Table 2). One interpretation proposes that patients 
with	 a	 combination	 of	 increased	 amniotic	 fluid	 IL-	6	 and	 CXCL10	
concentrations	had	a	more	severe	form	of	intra-	amniotic	inflamma-
tion	than	those	with	an	isolated	elevation	in	either	CXCL10	or	IL-	6	
concentration, in whom the clinical course leading to preterm deliv-
ery may be more indolent in nature. This could explain the trend 
toward	a	more	frequent	 involvement	of	the	fetus	 in	patients	with	
an	elevation	in	both	amniotic	fluid	CXCL10	and	IL-	6	concentrations.
CXCL10	has	been	implicated	in	the	pathophysiology	of	sepsis	by	
recruiting neutrophils, macrophages, and T cells.291,292 Previous stud-
ies	demonstrated	that	there	is	an	upregulation	of	CXCL10	leading	to	
subsequent	 activation	 of	 its	 receptor	 (CXCR3)	 during	 infection	 and	
inflammation.293,294 In an experimental model of septic shock induced 
by cecal ligation and puncture, it has been shown that plasma and 
peritoneal	 fluid	 CXCL10	 concentrations	 increase.295	 Additionally,	
CXCL10	knockout	mice	and	wild-	type	mice	treated	with	anti-	CXCL10	
IgG antibody had less cytokine production and increased survival.296 
Similar	observations	were	 found	 for	 the	 role	of	CXCR3	during	 sep-
sis;	 it	 regulates	 NK-	 and	 T-	cell	 trafficking.	 Moreover,	 in	 a	 septic	
shock	model	 for	 mice,	 the	 blockade	 of	 CXCR3	 decreases	 systemic	
inflammation and improves survival.296,297	CXCL10	and	CXCR3	also	
play	a	role	in	human	sepsis,	and	plasma	CXCL10	is	a	predictor	of	sep-
tic shock.298–300	Collectively,	 these	data	 suggest	 that	CXCL10	 is	 an	
inflammatory mediator involved in the response to microorganisms 
and bacterial products; therefore, some cases of advanced infections 
could	have	elevated	concentrations	of	both	IL-	6	and	CXCL10.	An	ele-
vated	amniotic	fluid	concentration	of	CXCL10	would	be	more	mean-
ingful to identify the patient at risk of chronic inflammatory lesions of 
the	placenta	if	the	amniotic	fluid	concentration	of	IL-	6	is	not	elevated.
4.5 | Strengths and limitations
The major strengths of this study are as follows: pathologists were 
blinded to the obstetrical diagnoses and outcomes; standardized pro-
tocols were utilized for placental examinations; and the consideration 
of isolated rather than any increase in the concentration of either 
amniotic	fluid	CXCL10	or	amniotic	fluid	IL-	6.	Limitations	were	related	
to	 the	 small	 sample	 size.	 Further	 studies	 are	 required	 to	 character-
ize the temporal relationship between exposure to microbial prod-
ucts or other insults and the amniotic fluid changes in cytokines and 
chemokines.	Moreover,	large	studies	are	necessary	to	determine	the	
diagnostic	indices	of	CXCL10	elevation	to	identify	the	patient	at	risk	
of chronic placental inflammation.
5  | CONCLUSION
An	isolated	elevation	 in	amniotic	fluid	CXCL10	concentration	 (with-
out	a	concomitant	elevation	in	IL-	6	concentration)	is	associated	with	
the delivery of a placenta with histologic chronic chorioamnionitis or 
lesions	consistent	with	maternal	anti-	fetal	rejection,	whereas	an	iso-
lated	increase	in	amniotic	fluid	IL-	6	concentration	is	associated	with	
the delivery of a placenta with acute histologic chorioamnionitis.
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